Teva Reports Positive Phase 2a Results For TEV-408 In Celiac Disease

Teva Pharmaceutical (TEVA) reported positive topline results from a Phase 2a study of TEV 408, an anti-interleukin-15 monoclonal antibody, for treating celiac disease. The study met its primary endpoint, showing significant prevention of gluten-induced intestinal damage compared to placebo. The company plans to present further data at a future scientific meeting. TEVA shares rose 2.96% in pre-market trading.

Teva Pharmaceutical Industries Ltd. announced that its experimental drug for immune disorders met the primary endpoint in a mid-stage clinical trial. The company stated that the results showed a statistically significant improvement in patients. This development could potentially expand Teva's portfolio in the immune disorder treatment market.

Teva Pharma (TEVA) stock rose 3.3% in pre-market trading after its TEV ’408 drug showed positive results in a Phase 2a trial for celiac disease. The trial met its primary endpoint and showed a favorable safety profile. Teva is also advancing the drug for vitiligo in a Phase 2b study. The company held an investor call to discuss the data, and the stock's performance was driven by this news rather than broader market trends.

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.

The Tel Aviv Stock Exchange rose after the Bank of Israel cut interest rates to 3.25%. The Tel Aviv 35 Index gained 0.22%, while Dimri led gains with a 5.47% rise. OPC Energy fell 4.67%, the biggest decline. Key movers included Elbit Systems, Teva, and Ormat, which rose, and Camtek and Tower Semiconductor, which fell.

President Trump expanded his Most-Favored-Nation drug pricing initiative to 26 companies, covering 89% of the branded drug market. New participants include Alcon, Astellas Pharma, and Teva, among others, agreeing to tie Medicaid drug prices to those in other developed countries. The deals also involve $19.6 billion in U.S. manufacturing investments. According to HHS Secretary Robert F. Kennedy Jr., the agreements cover nine out of 10 drugs used by Americans.